We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
AbbVie and Calico Announce a Novel Collaboration
News

AbbVie and Calico Announce a Novel Collaboration

AbbVie and Calico Announce a Novel Collaboration
News

AbbVie and Calico Announce a Novel Collaboration

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "AbbVie and Calico Announce a Novel Collaboration"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

AbbVie and Calico have announced a novel R&D collaboration intended to help the two companies discover, develop and bring to market new therapies for patients with age-related diseases, including for neurodegeneration and cancer.

Calico is the Google-backed life sciences company that is led by Arthur D. Levinson Ph.D. (former chairman and CEO of Genentech) and Hal V. Barron, M.D. (former Executive Vice President and Chief Medical Officer of Genentech). The agreement paves the way for Calico to establish a world-class research and development facility in the San Francisco Bay Area.

Under the agreement, the companies will combine their complementary strengths to accelerate the availability of new therapies for age-related diseases:

• Calico will use its scientific expertise to establish a world-class research and development facility, with a focus on drug discovery and early drug development
• AbbVie will provide scientific and clinical development support and its commercial expertise to bring new discoveries to market

"This collaboration demonstrates our commitment to exploring new areas of medicine and innovative approaches to drug discovery and development that augments our already robust pipeline," said Richard A. Gonzalez, Chairman of the Board and Chief Executive Officer, AbbVie. "We are pleased to be working with such outstanding scientists as Art Levinson, Hal Barron and their team. The potential to help improve patients' lives with new therapies is enormous."

"Our relationship with AbbVie is a pivotal event for Calico, whose mission is to develop life-enhancing therapies for people with age-related diseases. It will greatly accelerate our efforts to understand the science of aging, advance our clinical work, and help bring important new therapies to patients everywhere," said Art Levinson, CEO and founder of Calico.

Details of the Research Collaboration

• AbbVie and Calico will each initially provide up to $250 million to fund the collaboration with the potential for both sides to contribute an additional $500 million
• Calico will be responsible for research and early development during the first five years and continue to advance collaboration projects through Phase 2a for a ten year period
• AbbVie will support Calico in its early R&D efforts and, following completion of Phase 2a studies, will have the option to manage late-stage development and commercial activities
• Both parties will share costs and profits equally

"We are thrilled to have the opportunity to work with the many outstanding scientists at AbbVie to ensure that the important science at Calico is advanced quickly to benefit patients," said Hal Barron, M.D., President of Research and Development at Calico.

"We are extremely proud to have our research teams partnering with Calico as we aim to address treatments for diseases of aging," said Michael Severino, M.D., Executive Vice President, Research and Development, and Chief Scientific Officer, AbbVie. "Our broad R&D experience and capabilities will complement Calico's biotechnology expertise and innovative scientific approaches. Together, we are confident that we will bring new therapeutic solutions to patients."

Calico expects to begin filling critical positions immediately and plans to establish a substantial team of scientists and research staff in the San Francisco Bay Area.

Advertisement